Allogeneic iPSC-derived Cardiomyocyte Therapy in Patients With Worsening Ischemic Heart Failure

Inclusion Criteria: * Aged 35-75 (including 35 and 75). * Signed the Informed Consent Form (ICF). * Have chronic left ventricular dysfunction. * Have NYHA Class III-IV cardiac function even after improved medication for the treatment of advanced chronic heart failure. * Have indications for Coronary Artery Bypass Grafting. * LVEF \< 40% as determined by echocardiogram (data collected up to 6 months prior to inclusion evaluation are valid; data collected within 1 month since a myocardial infarction are invalid). * Weakening or absence of segmental regional wall motion as determined by standard imaging Exclusion Criteria: * PRA ≥ 20% or DSA-positive * Patient received ICD transplantation, CRT or similar treatment. * Patients with valvular heart disease or received heart valvular disease * Patients received treatment of percutaneous transluminal coronary intervention (PCI) * Patients with atrial fibrillation * Patients previously suffered sustained ventricular tachycardia or sudden cardiac death. * Baseline glomerular filtration rate \<30ml/min/1.73m2. * Liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three times the ULN. * Hematological abnormality: A hematocrit \<25% as determined by HCT, white blood cell\<2500/ul or platelet values \<100000/ul without another explanation. * Known, serious radiographic contrast allergy, penicillin allergy, streptomycin allergy. * Coagulopathy (INR\>1.3) not due to a reversible cause. * Contra-indication to performance …